A

Armata Pharmaceuticals Inc
AMEX:ARMP

Watchlist Manager
Armata Pharmaceuticals Inc
AMEX:ARMP
Watchlist
Price: 1.59 USD 3.92%
Market Cap: 57.5m USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one ARMP stock under the Base Case scenario is 1.98 USD. Compared to the current market price of 1.59 USD, Armata Pharmaceuticals Inc is Undervalued by 20%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ARMP Relative Value
Base Case
1.98 USD
Undervaluation 20%
Relative Value
Price
A
Worst Case
Base Case
Best Case

Valuation Multiples

11.1
P/S
P/S
Price to Sales
11.1
vs History
85
vs Industry
39
Median 3Y
20.9
Median 5Y
26.5
Industry
7
Forward
10.3
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-2.1
Median 5Y
-2.9
Industry
21.8
Forward
-0.8
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-2.4
Median 5Y
-3.4
Industry
19.3
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-5.2
Median 5Y
-4.7
Industry
22.7
More Details
Negative
P/B
P/B
Price to Book Value
N/A
vs History
vs Industry
Median 3Y
-1
Median 5Y
2.4
Industry
2.4
More Details
20
EV/S
EV/S
Enterprise Value to Sales
20
vs History
69
vs Industry
29
Median 3Y
22.8
Median 5Y
25.9
Industry
7.3
Forward
18.5
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.8
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-2.9
Median 5Y
-2.9
Industry
4
Forward
-2.1
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-2.8
Median 5Y
-2.8
Industry
3.7
Forward
-2
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-3
Median 5Y
-3.2
Industry
4.5
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-2.6
Median 5Y
-2.9
Industry
3.2
More Details
1.4
EV/IC
EV/IC
Enterprise Value to IC
1.4
vs History
79
vs Industry
55
Median 3Y
1.6
Median 5Y
1.7
Industry
4.5
More Details

Multiples Across Competitors

ARMP Competitors Multiples
Armata Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Armata Pharmaceuticals Inc
AMEX:ARMP
57.5m USD 11.1 -3 -2.5 -2.4
FR
Pharnext SCA
OTC:PNEXF
6T USD 35 020 097 -166 445.3 -202 117.7 -199 811.3
US
Abbvie Inc
NYSE:ABBV
344.2B USD 6.1 81.2 16 24.2
US
Amgen Inc
NASDAQ:AMGN
154.2B USD 4.6 37.7 15.5 27.4
US
Gilead Sciences Inc
NASDAQ:GILD
130.2B USD 4.5 271.3 10.7 13.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
129.6B USD 11.8 -241.8 26.5 27.8
US
Epizyme Inc
F:EPE
94.1B EUR 2 011.7 -513.3 -559 -544.1
AU
CSL Ltd
ASX:CSL
121.6B AUD 5.1 28.4 17.5 21.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
65B USD 4.6 14.7 9.2 10.2
US
Seagen Inc
F:SGT
39.3B EUR 19.4 -59.4 -64 -57.7
NL
argenx SE
XBRU:ARGX
34.6B EUR 17.9 47.1 -2 663.7 -1 785.9
P/S Multiple
Revenue Growth P/S to Growth
US
A
Armata Pharmaceuticals Inc
AMEX:ARMP
Average P/S: 3 183 835.8
11.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
35 020 097
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.1
7%
0.9
US
Amgen Inc
NASDAQ:AMGN
4.6
4%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.5
3%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
11.8
10%
1.2
US
E
Epizyme Inc
F:EPE
2 011.7
N/A N/A
AU
CSL Ltd
ASX:CSL
5.1
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.6
6%
0.8
US
S
Seagen Inc
F:SGT
19.4
30%
0.6
NL
argenx SE
XBRU:ARGX
17.9
39%
0.5
P/E Multiple
Earnings Growth PEG
US
A
Armata Pharmaceuticals Inc
AMEX:ARMP
Average P/E: 80.1
Negative Multiple: -3 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -166 445.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
81.2
87%
0.9
US
Amgen Inc
NASDAQ:AMGN
37.7
44%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
271.3
187%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -241.8 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -513.3 N/A N/A
AU
CSL Ltd
ASX:CSL
28.4
16%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.7
11%
1.3
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.4 N/A N/A
NL
argenx SE
XBRU:ARGX
47.1
28%
1.7
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
A
Armata Pharmaceuticals Inc
AMEX:ARMP
Average EV/EBITDA: 15.9
Negative Multiple: -2.5 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -202 117.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
15.5
17%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.7
7%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.5
18%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -559 N/A N/A
AU
CSL Ltd
ASX:CSL
17.5
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
9.2
14%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -64 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 663.7 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
A
Armata Pharmaceuticals Inc
AMEX:ARMP
Average EV/EBIT: 20.8
Negative Multiple: -2.4 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -199 811.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
24.2
28%
0.9
US
Amgen Inc
NASDAQ:AMGN
27.4
31%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
13.4
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.8
15%
1.9
US
E
Epizyme Inc
F:EPE
Negative Multiple: -544.1 N/A N/A
AU
CSL Ltd
ASX:CSL
21.9
14%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.2
17%
0.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.7 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -1 785.9 N/A N/A

See Also

Summary
ARMP intrinsic value, competitors valuation, and company profile.
DCF Valuation
ARMP stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ARMP stock valuation using valuation multiples.
Wall Street Estimates
ARMP price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ARMP stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 251,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.